Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Taxane
Docetaxel
Taxotere · DTX
A taxane whose hallmark fluid retention rarely translates into true kidney injury.
MildTaxane · approved 1996
Breast cancerProstate cancerNon-small-cell lung cancerGastric cancer
Signature kidney injury
Prerenal / Hemodynamic AKI
Docetaxel has low direct renal toxicity. Its characteristic fluid-retention syndrome (peripheral edema, effusions, weight gain) reflects increased capillary permeability rather than tubular injury; AKI directly attributable to docetaxel is uncommon and not well quantified, and the drug has been used successfully even in kidney-transplant recipients.
Source: García-Carro et al., Nephron 2022
Mechanism of kidney injury
No characteristic direct nephrotoxin effect. Cumulative capillary-permeability changes cause fluid retention and third-spacing, and, less often, hypersensitivity-related hemodynamic instability can produce prerenal physiology; the kidney parenchyma is generally spared.
Clinical presentation
Progressive peripheral edema, pleural/pericardial effusions, and weight gain accruing over cycles; renal function usually preserved, with any creatinine rise typically prerenal and reversible. Hypersensitivity reactions occur during infusion.
Onset
Fluid retention develops cumulatively (often after several cycles / cumulative dose); hypersensitivity reactions occur during infusion.
Reversibility
Reversible
Anticancer mechanism
Microtubule-stabilizing taxane that binds beta-tubulin, prevents microtubule depolymerization, arrests mitosis, and promotes apoptosis. Used in breast, prostate, lung, gastric, and head-and-neck cancers.
Management
Manage fluid retention with continued corticosteroid prophylaxis and diuretics as needed; treat prerenal AKI with volume optimization. No drug-specific renal therapy is required.
Risk factors
- Omission or inadequate corticosteroid premedication (worsens fluid retention)
- Cardiac or volume-overload comorbidity
- Higher cumulative docetaxel dose
- Concurrent nephrotoxins and volume depletion
Prevention
- Corticosteroid premedication (e.g. dexamethasone starting the day before) to limit fluid retention and hypersensitivity
- Monitor weight, edema, and renal function across cycles
- Maintain euvolemia and avoid additive nephrotoxins
Note · Fluid retention is the signature toxicity; direct renal toxicity is low and the agent is non-renally cleared.
Clinical depth
Renal dose adjustment
Hepatically (CYP3A4) metabolized and biliary excreted - no renal dose adjustment; reduce dose (or avoid) with significant hepatic dysfunction/elevated bilirubin and transaminases, which raise toxicity risk.
Dialyzability & ESKD dosing
Highly protein-bound, large volume of distribution, non-renally cleared; not dialyzable. Tolerated in dialysis and transplant patients with standard dosing and supportive care.
Differential diagnosis
Docetaxel fluid-retention syndrome with prerenal physiology vs cardiac/renal volume overload vs nephrotic-range proteinuria (which docetaxel does not cause). Bland urine with low albumin from third-spacing, not heavy proteinuria, points to the taxane.
Monitoring
- Weight and clinical edema/effusions each cycle
- LFTs/bilirubin before dosing (drives dose adjustment)
- CBC for neutropenia; creatinine if volume status changes
Key trials & series
- Nagahisa Transplant Proc 2024 case of safe docetaxel use after kidney transplantation
Clinical pearls
- Steroid premedication is what keeps docetaxel fluid retention in check - skipping it worsens edema.
- Fluid retention reflects capillary permeability, not kidney injury; creatinine usually stays normal.
- Docetaxel can be given in transplant/dialysis patients because it is non-renally cleared.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of taxanes.
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Peripheral neuropathy (taxanes, vinca)
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Hypersensitivity (taxane vehicles)
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkOnconephrology: Update in Anticancer Drug-Related Nephrotoxicity.García-Carro C et al. · Nephron 2022 · PMID 35717937Reviews taxane renal safety, noting low direct nephrotoxicity.PMIDSafety of Docetaxel in a Patient with Metastatic Castration-Resistant Prostate Cancer After Kidney Transplantation: A Case Report.Nagahisa C et al. · Transplant Proc 2024 · PMID 38548511Illustrates tolerability of docetaxel in a kidney-transplant recipient, consistent with low direct renal toxicity.PMIDRe-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.Picard M et al. · Clin Rev Allergy Immunol 2015 · PMID 24740483Covers docetaxel hypersensitivity and fluid-retention context, including premedication and desensitization.PMIDOnconephrology: The intersections between the kidney and cancer.Rosner MH et al. · CA Cancer J Clin 2020 · PMID 32853404Authoritative review contextualizing chemotherapy-associated renal effects.
Related agents
Other agents sharing the same signature kidney injury.